Protective effects of omega-3 fatty acids in dogs with myxomatous mitral valve disease stages B2 and C

Myxomatous mitral valve disease (MMVD) is characterized by thickening of the valve leaflets and omega-3 (ω-3) supplementation has been associated with modulation of blood pressure (BP) and heart rate, improvement of doppler echocardiographic indices, antiarrhythmic, anti-inflammatory and anti-dislip...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-07, Vol.16 (7), p.e0254887
Main Authors: Nasciutti, Priscilla Regina, Moraes, Aline Tavares, Santos, Thaiz Krawczyk, Gonçalves Queiroz, Karine Kelly, Costa, Ana Paula Araújo, Amaral, Andressa Rodrigues, Fernando Gomes Olivindo, Rodrigo, Pontieri, Cristiana Ferreira Fonseca, Jeremias, Juliana Toloi, Vendramini, Thiago Henrique Annibale, Brunetto, Marcio Antonio, Carvalho, Rosângela de Oliveira Alves
Format: Article
Language:English
Subjects:
Animal sciences
Biology and Life Sciences
Biomarkers
Blood pressure
Cardiac arrhythmia
Cardiology
Cardiomyopathy
Cardiovascular disease
Diagnosis
Diet
Dietary supplements
Dogs
Doppler effect
Echocardiography
EKG
Electrocardiography
Evaluation
Fatty acids
Health aspects
Heart rate
Heart valve diseases
Heart valves
Hospitals
Inflammation
Ingestion
Laboratory animals
Laboratory tests
Medicine and Health Sciences
Mitral valve
Nutrition
Pets
Radiography
Research and Analysis Methods
Rheumatic heart disease
Thickening
Thorax
Valve leaflets
Vertebrae
Veterinary colleges
Veterinary medicine
Zoology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myxomatous mitral valve disease (MMVD) is characterized by thickening of the valve leaflets and omega-3 (ω-3) supplementation has been associated with modulation of blood pressure (BP) and heart rate, improvement of doppler echocardiographic indices, antiarrhythmic, anti-inflammatory and anti-dislipidemic effects in dogs and humans, although prospective studies of it single use are still absent in the veterinary literature. The objective of this study was to evaluate the influence of ω-3 supplementation in dogs with MMVD. Twenty-nine dogs were followed quarterly for 12 months by clinical evaluation, arterial blood pressure, electrocardiography, doppler echocardiography, thoracic radiography and laboratory tests including inflammatory mediators and cardiac biomarker blood concentrations. The dogs were classified in stages B2 and C, according to the classification proposed by ACVIM 2019. They were randomly assigned to either ω-3 group (ω-3G) or control group (CG). The ingestion of ω-3 reduced the chance of developing arrhythmias by 2.96 times (p = 0.003). The vertebral heart size (VHS) measurements were higher in the control group (p = 0.033). In conclusion, at the dosages used in this study, ω-3 dietary supplementation reduces the volumetric overload, has antiarrhythmic effect and keeps dogs with B2 and C stages of MMVD in milder stages of the disease.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0254887